A new study from Scripps Research suggests that some proof-of-concept HIV vaccines in early human trials generate antibodies that actively hinder the protection by degrading the vaccine's payload. The study's lead author, Andrew Ward stated that understanding how "off-target" antibodies may be undermining HIV vaccine prototypes allows for design improvement.